{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T20:58:19Z","timestamp":1794517099136,"version":"4.9.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001167","name":"Larry L. Hillblom Foundation","doi-asserted-by":"publisher","award":["2019-A-013-SUP"],"award-info":[{"award-number":["2019-A-013-SUP"]}],"id":[{"id":"10.13039\/100001167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARG-21-849773"],"award-info":[{"award-number":["AARG-21-849773"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A growing body of evidence shows that epileptic activity is frequently observed in patients with Alzheimer\u2019s disease (AD), implicating underlying excitatory-inhibitory imbalance. The distinction of whether the AD-epileptic phenotype represents a subset of patients or an underdiagnosed manifestation holds major therapeutic implications. Here, we quantified the excitatory-inhibitory imbalance in AD patients using magnetoencephalography and examined the relationships to AD pathophysiology\u2014amyloid-beta and tau, and to\u00a0epileptic activity. We used two metrics to quantify regional excitatory-inhibitory imbalance distinguishing between local hyperexcitability (\n                    <jats:italic>Neural excitability, quantified by\u00a0regional aperiodic spectral slope<\/jats:italic>\n                    ) and aberrant long-range synaptic input\u00a0integration (\n                    <jats:italic>Neural fragility, quantified by regional\u00a0linear dynamic instability<\/jats:italic>\n                    ). We found that amyloid-beta correlated with higher neural fragility and higher neural excitability, while tau and hypometabolism uniquely correlated with higher neural excitability. Importantly, the AD-epileptic phenotype showed a distinctive increase in neural fragility. Our findings demonstrate that AD pathophysiology is associated with diverse mechanisms of excitatory-inhibitory imbalance and that AD-epileptic phenotype represents a distinct group of patients with greater impairments in long-range synaptic input integration.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-62798-4","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T13:49:06Z","timestamp":1756216146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Distinct manifestations of excitatory-inhibitory imbalance associated with amyloid-\u03b2 and tau in patients with Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4217-8785","authenticated-orcid":false,"given":"Kamalini G.","family":"Ranasinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-7229","authenticated-orcid":false,"given":"Kiwamu","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faatimah","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Yballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel H.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0848","authenticated-orcid":false,"given":"Katherine P.","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3144-2085","authenticated-orcid":false,"given":"Heidi E.","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Vossel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4458-113X","authenticated-orcid":false,"given":"William","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-4265","authenticated-orcid":false,"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikantan S.","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"62798_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Prim. 7, 33 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"62798_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper, B. & Karran, E. The cellular phase of Alzheimer\u2019s disease. Cell 164, 603\u2013615 (2016).","journal-title":"Cell"},{"key":"62798_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrn.2016.141","volume":"17","author":"JJ Palop","year":"2016","unstructured":"Palop, J. J. & Mucke, L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 17, 777\u2013792 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"62798_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.cell.2012.02.046","volume":"149","author":"L Verret","year":"2012","unstructured":"Verret, L. et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708\u2013721 (2012).","journal-title":"Cell"},{"key":"62798_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","volume":"55","author":"JJ Palop","year":"2007","unstructured":"Palop, J. J. et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer\u2019s disease. Neuron 55, 697\u2013711 (2007).","journal-title":"Neuron"},{"key":"62798_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109855","volume":"37","author":"CW Chang","year":"2021","unstructured":"Chang, C. W., Evans, M. D., Yu, X., Yu, G. Q. & Mucke, L. Tau reduction affects excitatory and inhibitory neurons differently, reduces excitation\/inhibition ratios, and counteracts network hypersynchrony. Cell Rep. 37, 109855 (2021).","journal-title":"Cell Rep."},{"key":"62798_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1126\/science.1194653","volume":"330","author":"KA Vossel","year":"2010","unstructured":"Vossel, K. A. et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science 330, 198 (2010).","journal-title":"Science"},{"key":"62798_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1126\/science.1141736","volume":"316","author":"ED Roberson","year":"2007","unstructured":"Roberson, E. D. et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer\u2019s disease mouse model. Science 316, 750\u2013754 (2007).","journal-title":"Science"},{"key":"62798_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-024-00712-0","volume":"19","author":"MZ Zhong","year":"2024","unstructured":"Zhong, M. Z., Peng, T., Duarte, M. L., Wang, M. & Cai, D. Updates on mouse models of Alzheimer\u2019s disease. Mol. Neurodegener. 19, 23 (2024).","journal-title":"Mol. Neurodegener."},{"key":"62798_CR10","first-page":"18","volume":"8","author":"S Tok","year":"2022","unstructured":"Tok, S., Crauwels, D. & Drinkenburg, W. H. A characterization of epileptiform activity associated with TAU seeding and amyloid pathology in the APPK- M670\/671NL.PS1\/L166P and APP-KI animal models. J. Neurol. Exp. Neurosci. 8, 18\u201331 (2022).","journal-title":"J. Neurol. Exp. Neurosci."},{"key":"62798_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2165\/00002512-200320110-00001","volume":"20","author":"M Mendez","year":"2003","unstructured":"Mendez, M. & Lim, G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 20, 791\u2013803 (2003).","journal-title":"Drugs Aging"},{"key":"62798_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ana.24794","volume":"80","author":"KA Vossel","year":"2016","unstructured":"Vossel, K. A. et al. Incidence and impact of subclinical epileptiform activity in Alzheimer\u2019s disease. Ann. Neurol. 80, 858\u2013870 (2016).","journal-title":"Ann. Neurol."},{"key":"62798_CR13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nm.4330","volume":"23","author":"AD Lam","year":"2017","unstructured":"Lam, A. D. et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer\u2019s disease. Nat. Med 23, 678\u2013680 (2017).","journal-title":"Nat. Med"},{"key":"62798_CR14","doi-asserted-by":"publisher","first-page":"e2259","DOI":"10.1212\/WNL.0000000000010612","volume":"95","author":"AD Lam","year":"2020","unstructured":"Lam, A. D. et al. Association of epileptiform abnormalities and seizures in Alzheimer disease. Neurology 95, e2259\u2013e2270 (2020).","journal-title":"Neurology"},{"key":"62798_CR15","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awab442","volume":"145","author":"KG Ranasinghe","year":"2022","unstructured":"Ranasinghe, K. G. et al. Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer\u2019s disease. Brain 145, 744\u2013753 (2022).","journal-title":"Brain"},{"key":"62798_CR16","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1001\/jamaneurol.2013.136","volume":"70","author":"KA Vossel","year":"2013","unstructured":"Vossel, K. A. et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 70, 1158\u20131166 (2013).","journal-title":"JAMA Neurol."},{"key":"62798_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neurobiolaging.2018.11.022","volume":"76","author":"J Voglein","year":"2019","unstructured":"Voglein, J. et al. Seizures as an early symptom of autosomal dominant Alzheimer\u2019s disease. Neurobiol. Aging 76, 18\u201323 (2019).","journal-title":"Neurobiol. Aging"},{"key":"62798_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/brain\/awq033","volume":"133","author":"S Jayadev","year":"2010","unstructured":"Jayadev, S. et al. Alzheimer\u2019s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 133, 1143\u20131154 (2010).","journal-title":"Brain"},{"key":"62798_CR19","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/brain\/awl237","volume":"129","author":"L Cabrejo","year":"2006","unstructured":"Cabrejo, L. et al. Phenotype associated with APP duplication in five families. Brain 129, 2966\u20132976 (2006).","journal-title":"Brain"},{"key":"62798_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3389\/fneur.2019.01151","volume":"10","author":"I Gureviciene","year":"2019","unstructured":"Gureviciene, I. et al. Characterization of epileptic spiking associated with brain amyloidosis in APP\/PS1 Mice. Front Neurol. 10, 1151 (2019).","journal-title":"Front Neurol."},{"key":"62798_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrn2967","volume":"12","author":"LM Ittner","year":"2011","unstructured":"Ittner, L. M. & Gotz, J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer\u2019s disease. Nat. Rev. Neurosci. 12, 65\u201372 (2011).","journal-title":"Nat. Rev. Neurosci."},{"key":"62798_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00401-017-1674-1","volume":"133","author":"RJ Hatch","year":"2017","unstructured":"Hatch, R. J., Wei, Y., Xia, D. & Gotz, J. Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. Acta Neuropathol. 133, 717\u2013730 (2017).","journal-title":"Acta Neuropathol."},{"key":"62798_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/brain\/awz060","volume":"142","author":"MA Busche","year":"2019","unstructured":"Busche, M. A. Tau suppresses neuronal activity in vivo, even before tangles form. Brain 142, 843\u2013846 (2019).","journal-title":"Brain"},{"key":"62798_CR24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41593-020-00744-x","volume":"23","author":"T Donoghue","year":"2020","unstructured":"Donoghue, T. et al. Parameterizing neural power spectra into periodic and aperiodic components. Nat. Neurosci. 23, 1655\u20131665 (2020).","journal-title":"Nat. Neurosci."},{"key":"62798_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45922-8","volume":"15","author":"N Brake","year":"2024","unstructured":"Brake, N. et al. A neurophysiological basis for aperiodic EEG and the background spectral trend. Nat. Commun. 15, 1514 (2024).","journal-title":"Nat. Commun."},{"key":"62798_CR26","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/s41593-021-00901-w","volume":"24","author":"A Li","year":"2021","unstructured":"Li, A. et al. Neural fragility as an EEG marker of the seizure onset zone. Nat. Neurosci. 24, 1465\u20131474 (2021).","journal-title":"Nat. Neurosci."},{"key":"62798_CR27","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1162\/NECO_a_00644","volume":"26","author":"D Sritharan","year":"2014","unstructured":"Sritharan, D. & Sarma, S. V. Fragility in dynamic networks: application to neural networks in the epileptic cortex. Neural Comput 26, 2294\u20132327 (2014).","journal-title":"Neural Comput"},{"key":"62798_CR28","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1093\/cercor\/bhw157","volume":"26","author":"L Fan","year":"2016","unstructured":"Fan, L. et al. The human brainnetome atlas: a new brain atlas based on connectional architecture. Cereb. Cortex 26, 3508\u20133526 (2016).","journal-title":"Cereb. Cortex"},{"key":"62798_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neuroimage.2019.01.024","volume":"189","author":"MA Colombo","year":"2019","unstructured":"Colombo, M. A. et al. The spectral exponent of the resting EEG indexes the presence of consciousness during unresponsiveness induced by propofol, xenon, and ketamine. Neuroimage 189, 631\u2013644 (2019).","journal-title":"Neuroimage"},{"key":"62798_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.06.078","volume":"158","author":"R Gao","year":"2017","unstructured":"Gao, R., Peterson, E. J. & Voytek, B. Inferring synaptic excitation\/inhibition balance from field potentials. Neuroimage 158, 70\u201378 (2017).","journal-title":"Neuroimage"},{"key":"62798_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj1895","volume":"9","author":"JD Lendner","year":"2023","unstructured":"Lendner, J. D. et al. Human REM sleep recalibrates neural activity in support of memory formation. Sci. Adv. 9, eadj1895 (2023).","journal-title":"Sci. Adv."},{"key":"62798_CR32","first-page":"3695","volume":"2020","author":"D Ehrens","year":"2020","unstructured":"Ehrens, D., Li, A., Aeed, F., Schiller, Y. & Sarma, S. V. Network fragility for seizure genesis in an acute in vivo model of epilepsy. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2020, 3695\u20133698 (2020).","journal-title":"Annu. Int. Conf. IEEE Eng. Med. Biol. Soc."},{"key":"62798_CR33","doi-asserted-by":"crossref","unstructured":"Chauhan, P., Philip, S. E., Chauhan, G. & Mehra, S. The anatomical basis of seizures. In Epilepsy, Ch. 2 (Exon Publications, Brisbane, AU, 2022).","DOI":"10.36255\/exon-publications-epilepsy-anatomical-basis"},{"key":"62798_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02218-z","volume":"12","author":"J Ahmad","year":"2022","unstructured":"Ahmad, J. et al. From mechanisms to markers: novel noninvasive EEG proxy markers of the neural excitation and inhibition system in humans. Transl. Psychiatry 12, 467 (2022).","journal-title":"Transl. Psychiatry"},{"key":"62798_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1755-5949.2011.00251.x","volume":"18","author":"D Friedman","year":"2012","unstructured":"Friedman, D., Honig, L. S. & Scarmeas, N. Seizures and epilepsy in Alzheimer\u2019s disease. CNS Neurosci. Ther. 18, 285\u2013294 (2012).","journal-title":"CNS Neurosci. Ther."},{"key":"62798_CR36","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3233\/JAD-170925","volume":"63","author":"A Horvath","year":"2018","unstructured":"Horvath, A. et al. Prevalence, semiology, and risk factors of epilepsy in Alzheimer\u2019s disease: an ambulatory EEG study. J. Alzheimers Dis. 63, 1045\u20131054 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"62798_CR37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10548-023-00968-7","volume":"36","author":"CJ Stam","year":"2023","unstructured":"Stam, C. J., van Nifterick, A. M., de Haan, W. & Gouw, A. A. Network hyperexcitability in early Alzheimer\u2019s disease: is functional connectivity a potential biomarker? Brain Topogr. 36, 595\u2013612 (2023).","journal-title":"Brain Topogr."},{"key":"62798_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33973-8","volume":"13","author":"AM van Nifterick","year":"2023","unstructured":"van Nifterick, A. M. et al. Resting-state oscillations reveal disturbed excitation-inhibition ratio in Alzheimer\u2019s disease patients. Sci. Rep. 13, 7419 (2023).","journal-title":"Sci. Rep."},{"key":"62798_CR39","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1007\/s00415-020-09937-7","volume":"267","author":"J Voglein","year":"2020","unstructured":"Voglein, J. et al. Seizures in Alzheimer\u2019s disease are highly recurrent and associated with a poor disease course. J. Neurol. 267, 2941\u20132948 (2020).","journal-title":"J. Neurol."},{"key":"62798_CR40","doi-asserted-by":"crossref","unstructured":"Vossel, K. et al. Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 78, 1345\u20131354 (2021).","DOI":"10.1001\/jamaneurol.2021.3310"},{"key":"62798_CR41","doi-asserted-by":"publisher","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","volume":"109","author":"PE Sanchez","year":"2012","unstructured":"Sanchez, P. E. et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model. Proc. Natl. Acad. Sci. USA 109, E2895\u2013E2903 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62798_CR42","doi-asserted-by":"publisher","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","volume":"33","author":"SL DeVos","year":"2013","unstructured":"DeVos, S. L. et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33, 12887\u201312897 (2013).","journal-title":"J. Neurosci."},{"key":"62798_CR43","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1523\/JNEUROSCI.3191-12.2013","volume":"33","author":"JK Holth","year":"2013","unstructured":"Holth, J. K. et al. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J. Neurosci. 33, 1651\u20131659 (2013).","journal-title":"J. Neurosci."},{"key":"62798_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1176\/appi.neuropsych.15060143","volume":"28","author":"RA Sarkis","year":"2016","unstructured":"Sarkis, R. A., Dickerson, B. C., Cole, A. J. & Chemali, Z. N. Clinical and neurophysiologic characteristics of unprovoked seizures in patients diagnosed with dementia. J. Neuropsychiatry Clin. Neurosci. 28, 56\u201361 (2016).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"62798_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209920","volume":"103","author":"AD Lam","year":"2024","unstructured":"Lam, A. D. et al. Association of seizure foci and location of tau and amyloid deposition and brain atrophy in patients with Alzheimer disease and seizures. Neurology 103, e209920 (2024).","journal-title":"Neurology"},{"key":"62798_CR46","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/brain\/awae231","volume":"148","author":"A Devulder","year":"2025","unstructured":"Devulder, A. et al. Epileptic activity on foramen ovale electrodes is associated with sleep and tau pathology in Alzheimer\u2019s disease. Brain 148, 506\u2013520 (2025).","journal-title":"Brain"},{"key":"62798_CR47","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41583-018-0067-3","volume":"19","author":"W Jagust","year":"2018","unstructured":"Jagust, W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat. Rev. Neurosci. 19, 687\u2013700 (2018).","journal-title":"Nat. Rev. Neurosci."},{"key":"62798_CR48","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1126\/science.aay0198","volume":"365","author":"B Zott","year":"2019","unstructured":"Zott, B. et al. A vicious cycle of beta amyloid-dependent neuronal hyperactivation. Science 365, 559\u2013565 (2019).","journal-title":"Science"},{"key":"62798_CR49","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1126\/science.1162844","volume":"321","author":"MA Busche","year":"2008","unstructured":"Busche, M. A. et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer\u2019s disease. Science 321, 1686\u20131689 (2008).","journal-title":"Science"},{"key":"62798_CR50","doi-asserted-by":"crossref","unstructured":"Chang, C. W., Shao, E. & Mucke, L. Tau: enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science 371, eabb8255 (2021).","DOI":"10.1126\/science.abb8255"},{"key":"62798_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40478-019-0754-y","volume":"7","author":"T Vogels","year":"2019","unstructured":"Vogels, T., Murgoci, A. N. & Hromadka, T. Intersection of pathological tau and microglia at the synapse. Acta Neuropathol. Commun. 7, 109 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"62798_CR52","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nn.4328","volume":"19","author":"JW Wu","year":"2016","unstructured":"Wu, J. W. et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085\u20131092 (2016).","journal-title":"Nat. Neurosci."},{"key":"62798_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103245","volume":"24","author":"M Das","year":"2021","unstructured":"Das, M. et al. Interdependence of neural network dysfunction and microglial alterations in Alzheimer\u2019s disease-related models. iScience 24, 103245 (2021).","journal-title":"iScience"},{"key":"62798_CR54","doi-asserted-by":"crossref","unstructured":"Milikovsky, D. Z. et al. Paroxysmal slow cortical activity in Alzheimer\u2019s disease and epilepsy is associated with blood-brain barrier dysfunction. Sci. Transl. Med. 11, eaaw8954 (2019).","DOI":"10.1126\/scitranslmed.aaw8954"},{"key":"62798_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2022.03.005","volume":"115","author":"MR LaPoint","year":"2022","unstructured":"LaPoint, M. R., Baker, S. L., Landau, S. M., Harrison, T. M. & Jagust, W. J. Rates of beta-amyloid deposition indicate widespread simultaneous accumulation throughout the brain. Neurobiol. Aging 115, 1\u201311 (2022).","journal-title":"Neurobiol. Aging"},{"key":"62798_CR56","doi-asserted-by":"crossref","unstructured":"Ranasinghe, K. G. et al. Neurophysiological signatures in Alzheimer\u2019s disease are distinctly associated with TAU, amyloid-beta accumulation, and cognitive decline. Sci. Transl. Med. 12, eaaz4069 (2020).","DOI":"10.1126\/scitranslmed.aaz4069"},{"key":"62798_CR57","doi-asserted-by":"crossref","unstructured":"Ranasinghe, K. G. et al. Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer\u2019s disease. Alzheimers Dement 17, 2009\u20132019 (2021).","DOI":"10.1002\/alz.12349"},{"key":"62798_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-021-00772-0","volume":"13","author":"EM Coomans","year":"2021","unstructured":"Coomans, E. M. et al. In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimers Res. Ther. 13, 35 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"62798_CR59","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/brain\/awab430","volume":"145","author":"AI Wiesman","year":"2022","unstructured":"Wiesman, A. I. et al. Spatially resolved neural slowing predicts impairment and amyloid burden in Alzheimer\u2019s disease. Brain 145, 2177\u20132189 (2022).","journal-title":"Brain"},{"key":"62798_CR60","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1093\/brain\/awad189","volume":"146","author":"DN Schoonhoven","year":"2023","unstructured":"Schoonhoven, D. N. et al. Tau protein spreads through functionally connected neurons in Alzheimer\u2019s disease: a combined MEG\/PET study. Brain 146, 4040\u20134054 (2023).","journal-title":"Brain"},{"key":"62798_CR61","doi-asserted-by":"crossref","unstructured":"Adams, J. N., Maass, A., Harrison, T. M., Baker, S. L. & Jagust, W. J. Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. Elife 8, e49132 (2019).","DOI":"10.7554\/eLife.49132"},{"key":"62798_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101372","volume":"69","author":"F Maestu","year":"2021","unstructured":"Maestu, F., de Haan, W., Busche, M. A. & DeFelipe, J. Neuronal excitation\/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology. Ageing Res. Rev. 69, 101372 (2021).","journal-title":"Ageing Res. Rev."},{"key":"62798_CR63","doi-asserted-by":"crossref","unstructured":"Senatorov, V. V., Jr. et al. Blood-brain barrier dysfunction in aging induces hyperactivation of TGFbeta signaling and chronic yet reversible neural dysfunction. Sci. Transl. Med. 11, eaaw8283 (2019).","DOI":"10.1126\/scitranslmed.aaw8283"},{"key":"62798_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/srep20119","volume":"6","author":"K Kam","year":"2016","unstructured":"Kam, K., Duffy, A. M., Moretto, J., LaFrancois, J. J. & Scharfman, H. E. Interictal spikes during sleep are an early defect in the Tg2576 mouse model of beta-amyloid neuropathology. Sci. Rep. 6, 20119 (2016).","journal-title":"Sci. Rep."},{"key":"62798_CR65","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement"},{"key":"62798_CR66","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7, 270\u2013279 (2011).","journal-title":"Alzheimers Dement"},{"key":"62798_CR67","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412\u20132414 (1993).","journal-title":"Neurology"},{"key":"62798_CR68","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1212\/WNL.0000000000002373","volume":"86","author":"KG Ranasinghe","year":"2016","unstructured":"Ranasinghe, K. G. et al. Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology 86, 600\u2013610 (2016).","journal-title":"Neurology"},{"key":"62798_CR69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/00029238.1980.11080014","volume":"20","author":"TA Pedley","year":"1980","unstructured":"Pedley, T. A. Interictal epileptiform discharges: discriminating characteristics and clinical correlations. Am. J. EEG Technol. 20, 101\u2013119 (1980).","journal-title":"Am. J. EEG Technol."},{"key":"62798_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1528-1167.2006.00654.x","volume":"47","author":"J Pillai","year":"2006","unstructured":"Pillai, J. & Sperling, M. R. Interictal EEG and the diagnosis of epilepsy. Epilepsia 47, 14\u201322 (2006).","journal-title":"Epilepsia"},{"key":"62798_CR71","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016).","journal-title":"Brain"},{"key":"62798_CR72","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl, M. et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron 89, 971\u2013982 (2016).","journal-title":"Neuron"},{"key":"62798_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.102025","volume":"24","author":"OH Lesman-Segev","year":"2019","unstructured":"Lesman-Segev, O. H. et al. Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. Neuroimage Clin. 24, 102025 (2019).","journal-title":"Neuroimage Clin."},{"key":"62798_CR74","doi-asserted-by":"crossref","unstructured":"Xia, M., Wang, J. & He, Y. BrainNet Viewer: a network visualization tool for human brain connectomics. PLoS One 8, e68910 (2013).","DOI":"10.1371\/journal.pone.0068910"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62798-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:54:29Z","timestamp":1757444069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62798-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62798"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62798-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.G.R., K.K., K.P.R., P.A.G., H.E.K., C.Y., F.S., K.V., G.D.R., J.H.K. and W.J. declare no competing interests relevant to this work. S.S.N. serves as a founding board member in Hippoclinic Inc., as a private consultant to MEGIN Inc. and is the PI for an industry contract from Ricoh MEG USA. B.L.M. has the following disclosures: serves as Medical Director for the John Douglas French Foundation; Scientific Director for the Tau Consortium; Director\/Medical Advisory Board of the Larry L. Hillblom Foundation; and Scientific Advisory Board Member for the National Institute for Health Research Cambridge Biomedical Research Center and its subunit, the Biomedical Research Unit in Dementia, UK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7957"}}